GKWIM
AKBA icon

Gerber Kawasaki Wealth & Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50
Closed – – 301
2021
Q3 		$0 Buy
+50
New +$143 ﹤0.01% 1166

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's AKBA Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Akebia Therapeutics (AKBA) in Q4 2021, closing a stake of 50 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in AKBA in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 133 funds tracked by Wall St. Rank hold AKBA as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Akebia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 50 Akebia Therapeutics shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Akebia Therapeutics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Akebia Therapeutics position peaked at $0 in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.